Managing Novartis’ pipeline in an era of fast innovation: Vas Narasimhan in conversation

While pharma companies aren’t known for their agility, this era of rapidly moving innovation requires constant review and re-evaluation of pipeline strategies to manage existing programs and anticipate needs for the next ones.

BioCentury sat down with Vas Narasimhan, CEO of  Novartis AG (SIX:NOVN; NYSE:NVS), during the J.P. Morgan Healthcare conference for a wide-ranging discussion on Novartis’ pipeline strategy, and how he views obstacles and opportunities for biotechs that can be both competitors and partnering prospects...